Update on the treatment options for multiple sclerosis

A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis

2006 • 3,172 citations

Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis

1996 • 2,410 citations

B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis

2008 • 2,239 citations

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

1998 • 2,049 citations

Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis

1993 • 2,032 citations

Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis

1995 • 1,903 citations

Intramuscular Interferon Beta-1A Therapy Initiated during a First Demyelinating Event in Multiple Sclerosis

2000 • 1,497 citations

Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis

2006 • 1,289 citations

A Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis

2003 • 1,228 citations

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group.

1993 • 1,227 citations

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study

2001 • 1,077 citations

Progressive Multifocal Leukoencephalopathy after Natalizumab Therapy for Crohn's Disease

2005 • 1,062 citations

Progressive Multifocal Leukoencephalopathy Complicating Treatment with Natalizumab and Interferon Beta-1a for Multiple Sclerosis

2005 • 1,060 citations

Oral Fingolimod (FTY720) for Relapsing Multiple Sclerosis

2006 • 1,043 citations

Progressive Multifocal Leukoencephalopathy in a Patient Treated with Natalizumab

2005 • 1,033 citations

Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis

2008 • 979 citations

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

2002 • 937 citations

Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis

1998 • 931 citations

Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes

2006 • 660 citations

Distinct Effector Cytokine Profiles of Memory and Naive Human B Cell Subsets and Implication in Multiple Sclerosis

2007 • 616 citations

Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN)

2002 • 557 citations

Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes

2006 • 552 citations

Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial

2009 • 538 citations

Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study

2007 • 506 citations

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

2008 • 479 citations

Oral simvastatin treatment in relapsing-remitting multiple sclerosis

2004 • 479 citations

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

2008 • 469 citations

Immune surveillance in multiple sclerosis patients treated with natalizumab

2006 • 428 citations

Interferon beta-1b in secondary progressive MS

2004 • 422 citations

Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double‐blind, placebo‐controlled trial

2007 • 416 citations

A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses

2006 • 355 citations

Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon β

2004 • 320 citations

Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis

2005 • 289 citations

Cladribine in treatment of chronic progressive multiple sclerosis

1994 • 284 citations

Treatment of Relapsing Paralysis in Experimental Encephalomyelitis by Targeting Th1 Cells through Atorvastatin

2003 • 281 citations

Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

2008 • 271 citations

Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function

2009 • 269 citations

Blood–brain barrier permeability and monocyte infiltration in experimental allergic encephalomyelitis

2004 • 265 citations

Treatment with laquinimod reduces development of active MRI lesions in relapsing MS

2005 • 228 citations

Interferon beta-1b in secondary progressive MS

2004 • 225 citations

The treatment of chronic progressive multiple sclerosis with cladribine.

1996 • 208 citations

Oral fumaric acid esters for the treatment of active multiple sclerosis: an open‐label, baseline‐controlled pilot study

2006 • 208 citations

Natalizumab effects on immune cell responses in multiple sclerosis

2006 • 206 citations

IM interferon β-1a delays definite multiple sclerosis 5 years after a first demyelinating event

2006 • 203 citations

Autologous haematopoietic stem-cell transplantation in multiple sclerosis

2008 • 202 citations

Oral fingolimod (FTY720) in multiple sclerosis

2009 • 193 citations

Efficacy of treatment of MS with IFNβ-1b or glatiramer acetate by monthly brain MRI in the BECOME study

2009 • 186 citations

Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-β in Lewis rats

2004 • 173 citations

Effect of Anti-CD25 Antibody Daclizumab in the Inhibition of Inflammation and Stabilization of Disease Progression in Multiple Sclerosis

2009 • 172 citations

Treatment of multiple sclerosis with an anti–interleukin‐2 receptor monoclonal antibody

2004 • 167 citations

Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results

2007 • 163 citations

The antipsoriatic agent dimethylfumarate immunomodulates T-cell cytokine secretion and inhibits cytokines of the psoriatic cytokine network

1998 • 163 citations

A Double‐Blind, Placebo‐Controlled, Randomized Trial of Cladribine in Relpaasing‐Remitting Multiple Sclerosis

1999 • 143 citations

Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis

2009 • 134 citations

Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy

2008 • 130 citations

GLANCE

2009 • 127 citations

Progressive multifocal leukoencephalopathy in patients with rheumatic diseases: Are patients with systemic lupus erythematosus at particular risk?

2008 • 124 citations

Oral High-Dose Atorvastatin Treatment in Relapsing-Remitting Multiple Sclerosis

2008 • 120 citations

Assessment: The use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review)

2008 • 117 citations

Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis

2008 • 109 citations

Benefits of high-dose, high-frequency interferon beta-1a in relapsing–remitting multiple sclerosis are sustained to 16 months: Final comparative results of the EVIDENCE trial

2005 • 104 citations

A randomized study of two interferon- beta treatments in relapsing–remitting multiple sclerosis

2006 • 102 citations

HMG‐CoA reductase inhibitor augments survival and differentiation of oligodendrocyte progenitors in animal model of multiple sclerosis

2005 • 102 citations

Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis

2008 • 93 citations

Combination Therapy With Interferon Beta-1a and Doxycycline in Multiple Sclerosis

2007 • 83 citations

Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS

2009 • 83 citations

A randomized blinded trial of combination therapy with cyclophosphamide in patients with active multiple sclerosis on interferon beta

2005 • 82 citations

Progressive multifocal leukoencephalopathy: report of three cases in HIV-negative hematological patients and review of literature

2007 • 80 citations

Regulation of gene expression associated with acute experimental autoimmune encephalomyelitis by Lovastatin

2004 • 73 citations

Getting specific: monoclonal antibodies in multiple sclerosis

2008 • 72 citations

Progressive multifocal leukoencephalopathy in a lymphoma patient with complete remission after treatment with cytostatics and rituximab: case report and review of the literature

2007 • 72 citations

Potential Risk of Progressive Multifocal Leukoencephalopathy With Natalizumab Therapy

2007 • 67 citations

Interferon beta in relapsing–remitting multiple sclerosis

2005 • 63 citations

Comparison of glatiramer acetate (Copaxone®) and interferon β-1b (Betaferon®) in multiple sclerosis patients: an open-label 2-year follow-up

2002 • 50 citations

Primary Progressive Multiple Sclerosis

2005 • 48 citations

Combination therapies for multiple sclerosis: scientific rationale, clinical trials, and clinical practice

2007 • 46 citations

Glatiramer acetate after mitoxantrone induction improves MRI markers of lesion volume and permanent tissue injury in MS

2008 • 27 citations

Effect of parenteral cladribine on relapse rates in patients with relapsing forms of multiple sclerosis: results of a 2-year, double-blind, placebo-controlled, crossover study

2009 • 25 citations

Monoclonal antibodies in the therapy of multiple sclerosis

2008 • 22 citations

Use of combination therapy with immunomodulators and immunosuppressants in treating multiple sclerosis

2004 • 18 citations

Compared benefit of approved and experimental immunosuppressive therapeutic approaches in multiple sclerosis

2007 • 18 citations

Combination therapy in multiple sclerosis

2005 • 18 citations

Clinical Trials of Multiple Sclerosis

1997 • 16 citations

Results from the CLARITY Study: a Phase III, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Oral Cladribine in Relapsing-Remitting Multiple Sclerosis (RRMS)

2009 • 6 citations

Immunosuppression in clinical practice

2008 • 5 citations

The 60th Annual Meeting of the American Academy of Neurology Chicago, Illinois, April 12-19, 2008

2008 • 1 citations